iCo Therapeutics Inc.

Recent News

  • iCo Therapeutics Announces Option Grants

    Vancouver, British Columbia--(Newsfile Corp. - October 26, 2020) -  iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today granted 1,535,000 stock options to directors, officers and a contractor.The stock options are exercisable at the price of $0.05 and will expire on October 25, 2025. The stock options shall vest as follows: 1/5 on today's date (the "Effective Date") and then 1/5 every six months until all options are vested. The closing price of the Company's shares on...

    2020-10-26 7:37 PM ET
  • iCo Therapeutics Inc. Announces That Oral Amphotericin B (iCo-019) Results Will Be Highlighted During the American Association of Pharmaceutical Scientists (AAPS) Virtual Meeting October 26 - November 3rd, 2020

    Vancouver, British Columbia--(Newsfile Corp. - October 21, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that two poster presentations regarding iCo's Oral Amphotericin B technology (iCo-019) will be highlighted at the AAPS 2020 PharmSci 360 Virtual Meeting October 26 - November 5, 2020.AAPS is the preeminent global scientific organization of more than 10,000 actively participating pharmaceutical scientists from industry, academia, government, and other related...

    2020-10-21 8:00 AM ET
  • iCo Therapeutics Announces Second Quarter 2020 Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - August 31, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter ended June 30, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated William Jarosz, CEO of iCo Therapeutics Inc., "Our Q2 results show a marked quarter over quarter decline in our operating expenses compared to Q1, having substantially completed our Australian Phase 1b trial...

    2020-08-31 4:58 PM ET
  • iCo Therapeutics Inc. Announces Publication of Oral Amphotericin B (iCo 019) Phase 1 Safety Study Results in Prestigious Infectious Diseases Journal

    Vancouver, British Columbia--(Newsfile Corp. - July 30, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today the publication of results of their Oral Amphotericin B (iCo 019) Phase 1a Study in one of the leading infectious diseases journals, Antimicrobial Agents and Chemotherapy entitled "Phase I Clinical Study to evaluate the safety, tolerability, and pharmacokinetics of a novel oral amphotericin B formulation (ICO-019) in healthy human subjects"...

    2020-07-30 8:57 PM ET
  • iCo Therapeutics Announces First Quarter 2020 Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - July 13, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter ended March 31, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated William Jarosz, CEO of iCo Therapeutics Inc., "We were pleased with the positive outcome from our Phase 1b study of our oral amphotericin B asset during the quarter and that we were...

    2020-07-13 7:36 PM ET
  • iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo-019) Results to be Presented at Prestigious American Pharmaceutical Sciences Meeting and Discussion Updates

    Vancouver, British Columbia--(Newsfile Corp. - June 22, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that the American Association of Pharmaceutical Scientists ("AAPS") has accepted two presentations regarding iCo's Oral Amphotericin B technology (iCo-019) for the AAPS 2020 PharmSci 360 Meeting to be held October 26-November 5, 2020 (the "PharmSci 360 Meeting"). AAPS is the preeminent global scientific organization of more than 10,000 actively...

    2020-06-22 7:33 PM ET
  • iCo Therapeutics Inc. Announces Q1 Interim Filing Update

    Vancouver, British Columbia--(Newsfile Corp. - May 29, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is providing an update on the status of the filing of its interim financial statements and accompanying management's discussion and analysis, and related CEO and CFO certifications for the three month period ended March 31, 2020 (collectively, the "Q1 Filings"). On March 18, 2020, the Canadian Securities Administrators announced that they will provide all issuers with a 45-day filing extension...

    2020-05-29 6:00 PM ET
  • iCo Therapeutics Announces 2019 Year End Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - May 19, 2020) -  iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the year ended December 31, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated William Jarosz, President and CEO of iCo Therapeutics Inc., "2019 represented a year of significant advances as we entered into a Phase 1b clinical trial for Oral Amphotericin B and we welcomed a...

    2020-05-19 8:00 AM ET